title: Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor.
abstract: Pancreatic cancer is characterized by invasive and metastatic potential. In this study, effects of the COX-2 inhibitor JTE-522 on cell viability, invasion, and invasion-related cellular properties were determined. JTE-522 (10 microM) induced a 75-90% reduction in invasion, compared to cells treated with a vehicle only, in the COX-2-expressing cells. In contrast, this inhibitor caused no significant reduction in cells lacking COX-2. Determinants of cell invasion, such as cell motility, adhesion to the extracellular matrix, and gelatinolytic activity of metalloproteinase, were also modulated in COX-2-positive pancreatic cancer cells. Thus, COX-2-specific inhibitors may be a useful anti-invasive therapeutic option in pancreatic cancer.
authors.affiliation: Department of Surgery and Clinical Oncology, Osaka University, Graduate School of Medicine, Suita City, Osaka, Japan.
authors.forename: Jiro
authors.initials: J
authors.lastname: Okami
authors.forename: Shoji
authors.initials: S
authors.lastname: Nakamori
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Hiraoka
authors.forename: Masanori
authors.initials: M
authors.lastname: Tsujie
authors.forename: Nobuyasu
authors.initials: N
authors.lastname: Hayashi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Masato
authors.initials: M
authors.lastname: Sakon
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
mesh_terms: D001557:Benzenesulfonates / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004341:Drug Evaluation; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000502:physiology*; D020782:Matrix Metalloproteinases / Q000494:pharmacology; D008565:Membrane Proteins; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D010080:Oxazoles / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology*; D014407:Tumor Cells, Cultured; D000096926:Benzenesulfonamides
chemical_list: D001557:Benzenesulfonates; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D020782:Matrix Metalloproteinases; D008565:Membrane Proteins; D010080:Oxazoles; D011451:Prostaglandin-Endoperoxide Synthases; C110453:4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; D000096926:Benzenesulfonamides; C496540:PTGS2 protein, human